Cargando…

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata

Detalles Bibliográficos
Autor principal:	Goggins, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3331774/ https://www.ncbi.nlm.nih.gov/pubmed/22517654 http://dx.doi.org/10.2337/db12-0233

Ejemplares similares

Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions
por: Carpenter, Eileen S., et al.
Publicado: (2023)

Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early pre-neoplastic pancreatic lesions
por: Carpenter, Eileen S., et al.
Publicado: (2023)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Increased Complement Activation in Human Type 1 Diabetes Pancreata
por: Rowe, Patrick, et al.
Publicado: (2013)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?
por: Monda, Vincenzo M., et al.
Publicado: (2020)

Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes
por: Shields, Emily J., et al.
Publicado: (2015)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Lu, Jinmiao, et al.
Publicado: (2023)

Evaluation of collagenase gold plus BP protease in isolating islets from human pancreata
por: Khiatah, Bashar, et al.
Publicado: (2018)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
por: Vemula, Hasitha, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
por: Kato, Shunsuke, et al.
Publicado: (2021)

Quantitative 3D OPT and LSFM datasets of pancreata from mice with streptozotocin-induced diabetes
por: Hahn, Max, et al.
Publicado: (2022)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
por: Darsalia, Vladimer, et al.
Publicado: (2018)

Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus
por: Dai, Chenggang, et al.
Publicado: (2022)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k97t6e0s3gf3j0nte69b0opcth